Pages

Wednesday, August 31, 2016

CurePSP and Light of Day Foundation Raise $120,000 for Neurodegenerative Diseases

ANDREW BLACK
Aug 31, 2016




The Light of Day foundation donated a matching grant of $80,000 to CurePSP, a nonprofit advocacy group focused towards neurodegenerative diseases to help fund their programs in patients and family care along with research, education and awareness. Because of the matched grant, CurePSP was able to raise a total of $120,000 from donors. 

About Light of Day Foundation


The Light of Day Foundation is dedicated to raising money and awareness for Parkinson’s disease and related neurodegenerative diseases such as progressive supranuclear palsy (PSP) and amyotrophic lateral sclerosis (ALS). Since its inception in 2000, Light of Day has raised over $3 million in the fight to find a cure for Parkinson’s disease.

Fun fact: In 1987, Michael J. Fox starred in a movie titled “Light of Day”. As many people are aware, Fox is diagnosed with Parkinson’s disease. 
The Light of Day Foundation has established itself as an internationally recognized concert tour in North America, Europe and Australia. Michael J. Fox has even been a featured guest as some of these concerts.

About CurePSP

CurePSP is a leading nonprofit advocacy organization focused on prime of life neurodegenerative diseases. It was founded in 1990, CurePSP has funded more than 170 research studies primarily in progressive supranuclear palsy (PSP) and the related disease corticobasal degeneration (CBD) and is one of the leading source of information and support for patients and their families, other caregivers, researchers, and doctors and allied healthcare professionals.

What is PSP?

Progressive supranuclear palsy (PSP) is an uncommon brain disorder that affects movement, control of walking (gait) and balance, speech, swallowing, vision, mood and behavior, and thinking. The disease results from damage to nerve cells in the brain. The exact cause of PSP is unknown. 

http://www.raredr.com/news/curepsp-light-of-day-raise-fund

No comments:

Post a Comment